These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17637939)

  • 1. Molecule of the month. Ticagrelor.
    Drug News Perspect; 2007 May; 20(4):264. PubMed ID: 17637939
    [No Abstract]   [Full Text] [Related]  

  • 2. Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes.
    Doggrell SA
    IDrugs; 2009 May; 12(5):309-17. PubMed ID: 19431096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.
    Storey RF; Melissa Thornton S; Lawrance R; Husted S; Wickens M; Emanuelsson H; Cannon CP; Heptinstall S; Armstrong M
    Platelets; 2009 Aug; 20(5):341-8. PubMed ID: 19637098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy.
    Christie DJ; Kottke-Marchant K; Gorman RT
    Platelets; 2008 Mar; 19(2):104-10. PubMed ID: 17852773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary components and human platelet activity.
    Dutta-Roy AK
    Platelets; 2002 Mar; 13(2):67-75. PubMed ID: 11897042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cationic propyl gallate and adenosine diphosphate for the measurement of aspirin effectivity with optical aggregometry.
    Motovska Z; Sujanova Z; Wimmerova S; Ardo J; Skrakova M; Widimsky P
    Transl Res; 2007 Oct; 150(4):246-52. PubMed ID: 17900512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comment on "hyperresponsiveness of platelets in ischemic stroke" by Fateh-Moghadam et al.
    Smout J; Cleanthis M; Stansby G
    Thromb Haemost; 2008 Jan; 99(1):239. PubMed ID: 18217162
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents.
    Madsen NJ; Holmes CE; Serrano FA; Sobel BE; Schneider DJ
    Am J Cardiol; 2007 Aug; 100(4):722-7. PubMed ID: 17697836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of ticagrelor debated as antiplatelet class approaches generic market.
    Morrow T
    Manag Care; 2011 Oct; 20(10):77-8. PubMed ID: 22111489
    [No Abstract]   [Full Text] [Related]  

  • 11. Cangrelor attenuates coated-platelet formation.
    Norgard NB; Hann CL; Dale GL
    Clin Appl Thromb Hemost; 2009; 15(2):177-82. PubMed ID: 18796456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Platelet antiaggregants in cardiovascular pathology].
    Merino A; Alegría E; Castelló R; Lorente D; Hidalgo R; Martínez Caro D
    Rev Med Univ Navarra; 1987; 31(4):191-4, 197-202. PubMed ID: 3126543
    [No Abstract]   [Full Text] [Related]  

  • 13. Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.
    Mathewkutty S; McGuire DK
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):541-9. PubMed ID: 19419262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of milrinone on platelet activation as determined by TEG platelet mapping.
    Wesley MC; McGowan FX; Castro RA; Dissanayake S; Zurakowski D; Dinardo JA
    Anesth Analg; 2009 May; 108(5):1425-9. PubMed ID: 19372315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin.
    Fox SC; May JA; Shah A; Neubert U; Heptinstall S
    Platelets; 2009 Jun; 20(4):250-9. PubMed ID: 19440925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of adrenaline and adenosine diphosphate induced platelet aggregation by Lansberg's hognose pit viper (Porthidium lansbergii hutmanni) venom.
    Lopez-Johnston JC; de Bosch N; Scannone H; Rodríguez-Acosta A
    Ann Hematol; 2007 Dec; 86(12):879-85. PubMed ID: 17891398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble P-selectin as a marker of in vivo platelet activation.
    Ferroni P; Martini F; Riondino S; La Farina F; Magnapera A; Ciatti F; Guadagni F
    Clin Chim Acta; 2009 Jan; 399(1-2):88-91. PubMed ID: 18835553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of aspirin in cardiovascular prevention: implications of aspirin resistance.
    Gasparyan AY; Watson T; Lip GY
    J Am Coll Cardiol; 2008 May; 51(19):1829-43. PubMed ID: 18466797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.